You are here

Epidiolex

How GW Pharmaceuticals Hit a Home Run in Q1

How GW Pharmaceuticals Hit a Home Run in Q1

Motley Fool

Flag link:

Zogenix's Positive Clinical Trial Wasn't Positive Enough

Zogenix's Positive Clinical Trial Wasn't Positive Enough

Motley Fool

Lennox-Gastaut Syndrome

clinical trials

Flag link:

GW's Epidiolex topped sales predictions, but investors bailed. What gives?

GW's Epidiolex topped sales predictions, but investors bailed. What gives?

Fierce Pharma

Flag link:

GW Pharma's cannabis-derived epilepsy medicine makes the cut in the European Union

GW Pharma's cannabis-derived epilepsy medicine makes the cut in the European Union

Endpoints

Flag link:

5 Things You'll Want to Watch With GW Pharmaceuticals

5 Things You'll Want to Watch With GW Pharmaceuticals

Motley Fool

Flag link:

GW Pharma scores another PhIII win for its cannabinoid in rare form of epilepsy

GW Pharma scores another PhIII win for its cannabinoid in rare form of epilepsy

Endpoints

clinical trials

tuberous sclerosis complex

Flag link:

Early Epidiolex sales push up GW Pharma's stock

Early Epidiolex sales push up GW Pharma's stock

BioPharma Dive

Flag link:

Cannabis-Based Drug (Still) Helps Epilepsy, but How Safe Is It?

Cannabis-Based Drug (Still) Helps Epilepsy, but How Safe Is It?

Motley Fool

clinical trials

Dravet syndrome

Flag link:

Why GW Pharmaceuticals Stock Jumped 17.7% in September

Why GW Pharmaceuticals Stock Jumped 17.7% in September

Moltey Fool

Flag link:

GW Pharma looks to dispel cannabis stigma with Epidiolex launch

GW Pharma looks to dispel cannabis stigma with Epidiolex launch

Fierce Pharma

Flag link:

Cannabis-Based Drug Companies Hopeful Epidiolex Will Pave the Way for Future Approvals

Cannabis-Based Drug Companies Hopeful Epidiolex Will Pave the Way for Future Approvals

BioSpace

Flag link:

GW Pharma, armed with best-case DEA decision, charts path to Epidiolex launch

GW Pharma, armed with best-case DEA decision, charts path to Epidiolex launch

Fierce Pharma

Flag link:

2 Blockbuster New Drug Launches Making Investors Nervous Right Now

2 Blockbuster New Drug Launches Making Investors Nervous Right Now

Motley Fool

Flag link:

These Epilepsy Drugmakers Are About to Brawl

These Epilepsy Drugmakers Are About to Brawl

Motley Fool

Flag link:

Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug

Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug

Xconomy

Dravet syndrome

clinical trials

Flag link:

Berkeley boy was ‘Patient X’ in first FDA-approved medicine derived from marijuana

Berkeley boy was ‘Patient X’ in first FDA-approved medicine derived from marijuana

San Francisco Chronicle, CA

clinical trials

Flag link:

CBD Oil Products Were Already Readily Available – How is Epidiolex Different?

CBD Oil Products Were Already Readily Available – How is Epidiolex Different?

CP Wire

Flag link:

CBD Oil Products Were Already Readily Available – How is Epidiolex Different?

Flag link:

FDA just approved the first prescription drug derived from marijuana: 4 outstanding questions

FDA just approved the first prescription drug derived from marijuana: 4 outstanding questions

Medical Marketing and Media

Flag link:

FDA approves country’s first medicine made from marijuana

FDA approves country’s first medicine made from marijuana

Stat

Dravet syndrome

Lennox-Gastaut Syndrome

Flag link:

Pages